NR4A Receptors Differentially Regulate NF-κB Signaling in Myeloid Cells

Abstract

Dysregulation of inflammatory responses is a hallmark of multiple diseases such as atherosclerosis and rheumatoid arthritis. As constitutively active transcription factors, NR4A nuclear receptors function to control the magnitude of inflammatory responses and in chronic inflammatory disease can be protective or pathogenic. Within this study, we demonstrate that TLR4 stimulation using the endotoxin lipopolysaccharide (LPS) rapidly enhances NR4A1–3 expression in human and murine, primary and immortalized myeloid cells with concomitant gene transcription and protein secretion of MIP-3α, a central chemokine implicated in numerous pathologies. Deficiency of NR4A2 and NR4A3 in human and murine myeloid cells reveals that both receptors function as positive regulators of enhanced MIP-3α expression. In contrast, within the same cell types and conditions, altered NR4A activity leads to suppression of LPS-induced MCP-1 gene and protein expression. An equivalent pattern of inflammatory gene regulation is replicated in TNFα-treated myeloid cells. We show that NF-κB is the critical regulator of NR4A1–3, MIP-3α, and MCP-1 during TLR4 stimulation in myeloid cells and highlight a parallel mechanism whereby NR4A activity can repress or enhance NF-κB target gene expression simultaneously. Mechanistic insight reveals that NR4A2 does not require DNA-binding capacity in order to enhance or repress NF-κB target gene expression simultaneously and establishes a role for NF-κB family member Relb as a novel NR4A target gene involved in the positive regulation of MIP-3α. Thus, our data reveal a dynamic role for NR4A receptors concurrently enhancing and repressing NF-κB activity in myeloid cells leading to altered transcription of key inflammatory mediators.

Staphylococcus aureus Phenol-Soluble Modulins α1–α3 Act as Novel Toll-Like Receptor (TLR) 4 Antagonists to Inhibit HMGB1/TLR4/NF-κB Signaling Pathway

“…The cytoplasmic fractions were separated by SDS-PAGE and transferred onto a polyvinylidenedifluoride membrane (Amersham Biosciences, Little Chalfont, UK). Immunoblotting was performed using antibodies against phospho-NF-κB p65 (1:1,000, Cell Signaling, Boston, MA, USA) or NF-κB p65 (1:1,000, Cell Signaling) ( 31 ). β-actin (1:1,000, Santa Cruz, Dallas, TX, USA) and LaminB1 (1:1,000, Santa Cruz, Dallas, TX, USA) were used as controls ( 32 ).…”

“…Cells were washed in PBS and lysed in Passive Lysis Buffer (Promega, Madison, WI, USA). The Dual-Luciferase reporter assay system (Promega) was used to quantitate both reporter genes by a POLARstar Omega multimode microplate spectrophotometer (BMG LABTECH) ( 31 ).…”

Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis

“…Written informed consent was obtained from all volunteers. Peripheral blood mononuclear cells (PBMCs) were isolated from blood as previously described [ 25 ]. Briefly, 20 ml of blood was collected, layered onto polymorphoprep solution (Axis-Shield, Dundee, UK) (1:1) and centrifuged for 35 min at 500× g and 20 °C.…”

The pro‐inflammatory effect of NR4A3 in osteoarthritis

“…18 Another study reported that NR4A family regulates NF-κB signalling in myeloid cells. 19 All these studies indicate that NR4A3 is involved in the regulation of ECM proteins. Furthermore, some other studies recently demonstrated NR4A3 to be involved in promoting apoptosis by inducing expression of pro-apoptotic genes in cancer cells, 20,21 while chondrocyte apoptosis is a valid target to modulate cartilage degeneration.…”